Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2003

View Archived Issues

ETB receptors and GIRKs: novel targets for the treatment of pain

New GSK-3 inhibitors with potential in diabetes, etc.

Gruenenthal patent covers new compounds for pain, depression, etc.

Shionogi researchers describe a novel series of HIV integrase inhibitors

New ADAM-10 inhibitors and their use in cancer and arthritis described by Exelixis

Novel NK1 antagonists for urinary incontinence and other uses in Kyorin pipeline

Noncalcemic vitamin D analogue designed by Wisconsin researchers

New anthelminthic agents patented by Kitasato Institute scientists

BMS-387032: a potent and selective CDK2 inhibitor undergoing clinical evaluation

Decolonization of the GI tract with ramoplanin: a novel option for management of VRE infection

Preclinical pharmacological activity of the novel aromatase inhibitor MEN-11066

Chiron presents antiangiogenic and antiproliferative agent targeting growth factor tyrosine kinases

Ariad compound for bone cancer/metastases a highlight of the AACR meeting

H3 Pharma acquires rights to vapreotide from Debiopharm

Patient dosing begins in Targeted Genetics' largest CF trial to date

Improved efficacy for niacin/lovastatin on lipid profile in hyperlipidemia

Santarus completes phase III patient enrollment in upper GI bleeding prevention trial

IX-1003 completes phase I testing

HCV-371 has no impact on HCV RNA levels in phase Ib study

Effective inhibition of thrombosis and moderate hemorrhage risk with melagatran in baboons

Pivotal European study of Adhibit commences enrollment

Better survival and response rate found with letrozole vs. tamoxifen in advanced breast cancer

Relationship between breast cancer risk and isoflavone consumption in Japanese women

Kosan achieves KOS-862 production goal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...